INOVATYON.

Trial name or title	Phase III international, randomised study of trabectedin plus pegylated liposomal doxorubicin (PLD) versus carboplatin plus PLD in patients with ovarian cancer progressing within 6‐12 months of last platinum (ID: NCT01379989)
Methods	Phase III multicentre RCT
Participants	558 women with ROC 6‐12 months after completion of first line treatment with platinum‐based chemotherapy
Interventions	trabectedin + PLD (30 mg/m²) versus carboplatin + PLD (30 mg/m²).
Outcomes	Primary: OS Secondary: PFS, ORR, CA125, duration of response, time to subsequent CT, safety
Starting date	Jun 2010
Contact information	Nicoletta Colombo
Notes	End Date: Dec 2017 Suspended due to the PLD shortage in 2011/12